Centiva Capital LP Invests $355,000 in Astrana Health, Inc. (NASDAQ:ASTH)

Centiva Capital LP bought a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 11,244 shares of the company’s stock, valued at approximately $355,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Pilgrim Partners Asia Pte Ltd bought a new position in Astrana Health during the 4th quarter worth about $40,000. Quarry LP grew its holdings in Astrana Health by 35.5% during the 4th quarter. Quarry LP now owns 1,799 shares of the company’s stock worth $57,000 after acquiring an additional 471 shares in the last quarter. KBC Group NV grew its holdings in Astrana Health by 108.4% during the 4th quarter. KBC Group NV now owns 2,530 shares of the company’s stock worth $80,000 after acquiring an additional 1,316 shares in the last quarter. US Bancorp DE grew its holdings in Astrana Health by 3,880.0% during the 4th quarter. US Bancorp DE now owns 4,776 shares of the company’s stock worth $151,000 after acquiring an additional 4,656 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its holdings in Astrana Health by 21.9% during the 4th quarter. Pictet Asset Management Holding SA now owns 7,075 shares of the company’s stock worth $223,000 after acquiring an additional 1,273 shares in the last quarter. 52.77% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ASTH has been the topic of several recent research reports. Robert W. Baird dropped their target price on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. Stifel Nicolaus decreased their price target on shares of Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Barclays initiated coverage on shares of Astrana Health in a research report on Tuesday, April 1st. They set an “equal weight” rating and a $36.00 price target for the company. Bank of America decreased their price target on shares of Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Finally, Truist Financial decreased their price target on shares of Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.29.

Astrana Health Stock Performance

Shares of Astrana Health stock opened at $29.67 on Monday. The firm has a market capitalization of $1.66 billion, a P/E ratio of 22.82, a PEG ratio of 1.37 and a beta of 1.00. The company has a quick ratio of 1.91, a current ratio of 1.91 and a debt-to-equity ratio of 0.60. The company has a 50 day moving average price of $30.90 and a 200 day moving average price of $36.14. Astrana Health, Inc. has a 52 week low of $23.12 and a 52 week high of $63.20.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.14). Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company’s revenue for the quarter was up 53.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.31 earnings per share. Sell-side analysts expect that Astrana Health, Inc. will post 1.15 EPS for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.